The Burden of Weight Loss Drugs: Is It Worth the Risk? Vantage with Palki Sharma
Weight loss drugs like Ozempic, Wegovy, and Mounjaro are being hailed as revolutionary, reshaping bodies, lives, and a booming $15 billion industry. But behind the hype lies a growing concern: shortages, black markets, and serious side effects ranging from stomach paralysis to suicidal thoughts. As demand soars and influencers drive the trend, experts warn we may be living through a massive human experiment.
See More
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 hours ago
- Hindustan Times
66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more
Ilene, a 66-year-old Instagram user, achieved an incredible weight transformation, shedding 18 kilos. What makes her journey truly inspiring is not just the weight she lost, but the fact that she accomplished it in her 60s. Ilene regularly shares glimpses of her experience, along with valuable lessons, diet tips, and lifestyle habits to help others on their own fitness journeys. Add these foods to your diet to make fat loss easier.(Shutterstock) Ilene, on June 12, shared an Instagram post to help her followers add the right kind of food items to their weight loss diet. 'Nobody told me this before I lost 40 lbs, so I'm telling you now. These foods mimic Ozempic and make fat loss 10x easier,' she wrote. Also read | Losing weight after 60: Healthy diet plan and exercise tips for seniors 1. Greek yogurt Why it helps: High-protein + fermented = big GLP-1 bump, steadier blood sugar, longer fullness. How to eat it: ¾ cup 2 % Greek yogurt + ½ cup berries + ½ scoop protein = 35 g protein breakfast or post-lift snack. 2. Sweet potatoes (especially cooled and reheated) Why it helps: Fiber + resistant starch ⟶ slower gastric emptying, steadier insulin, higher GLP-1 release. How to eat it: Roast, chill overnight, cube into salads or reheat with cinnamon and a dollop of Greek yogurt. 3. Berries Why they help: Polyphenols + fiber blunt glucose spikes and trigger satiety signals. How to eat them: Top oats, blend into protein shakes, or freeze-dry for a crunchy topping. 4. Eggs Why they help: Protein, healthy fats, and choline keep hunger hormones low and GLP-1 higher for hours. How to eat them: 2 whole eggs + ½ cup egg whites scramble → 30 g protein, add spinach for extra fiber. 5. Oats Why they help: β-glucan fiber thickens in your gut, slowing digestion and boosting GLP-1. Also read | How to lose weight after 50? Dietician shares simple steps to shed pounds and stay healthy How to eat them: ½ cup oats + water, stir in 1 scoop whey and 1 tbsp chia; microwave; top with berries ➜ protein + fiber powerhouse. 6. High-fiber veggies (broccoli, brussels sprouts, kale) Why they help: Insoluble + soluble fiber = slower carb absorption, more GLP-1, better gut health. How to eat them: Roast a sheet pan in olive oil & garlic; add to every plate (aim for 3 colors each meal). 7. Beans and lentils Why they help: Plant protein + resistant starch + fiber triple-team satiety hormones. How to eat them: ½ cup lentils in quinoa bowls or blend black beans into turkey-chili. 8. Avocado and nuts Why they help: Healthy monounsaturated fats delay gastric emptying and sustain GLP-1 signaling. How to eat them: ¼ avocado on Ezekiel toast or 10–12 almonds alongside Greek yogurt. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Time of India
18 hours ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
Time of India
18 hours ago
- Time of India
Was Luka Doncic's weight loss natural? NBA pro Gilbert Arenas says it's Ozempic as star credits diet and training
Luka Doncic lost a lot of weight (Image via Instagram / @ lukadoncic) Last season, Luka Doncic weighed 230 pounds while playing for the Dallas Mavericks. This season, he appears thinner, though. According to the most recent article of Men's Health, he began a new diet and exercise regimen that helped him lose almost 30 pounds. Nevertheless, a former NBA player, Gilbert Arenas, thinks there's more to that. He recently claimed that it was a side effect of the well-known weight-loss medication Ozempic. Luka Doncic 's dramatic weight loss sparks debate as Gilbert Arenas suggests Ozempic Recently, NBA veteran Gilbert Arenas took to his social media account and opened up about Luka Doncic's drastic weight loss. Even though the Slovenian basketball player once said that it was the result of diet and gym, the NBA icon thinks it's Ozempic. He said: 'Let's just be honest, man. The fact that he showed you with enough time for rest that Ozempic kicks in quickly, right? Listen, I heard all the soups and sh*t, and you know, he eats this, he eats that cold, right? All it takes is the f**k shot every week… So he's willing to do whatever it takes to get down. Now, the fact that he was doing what he was doing while he was fat…' He continued: 'What do you think about that? What do you think he's about to do to these now? He's about to go ham. I don't want to hear anything about no defense, okay? He's not losing away to play no defense. He lost weight to see if they could play some defense. We just got somebody to play defense. We don't need Luca to play defense. Let him average 39, 9, and 9. He's fine with me…' Luka Doncic recently joined the Los Angeles Lakers (Image via Instagram / @lukadoncic) However, Luka Doncic offered an alternative justification for his weight reduction. To lower inflammation and help his body's healing process, he has been intermittently fasting since June. He also admitted to the Men's Health recent issue that he reportedly eats two high-protein meals and one protein drink each day of the week. On the other hand, his team has worked on deceleration and footwork in the gym. He has further combined a low-sugar, gluten-free diet with weight and agility training as part of his exercise routine. However, what Gilbert Arenas said is just mere speculation and his opinion. Also read: How was Luka Doncic surprised by the Los Angeles Lakers? NBA pro celebrates $165M deal in Las Vegas with teammates and favorite band For real-time updates, scores, and highlights, follow our live coverage of the India vs England Test match here. Catch Rani Rampal's inspiring story on Game On, Episode 4. Watch Here!
